LY333328治疗实验性耐甲氧西林金黄色葡萄球菌心内膜炎的疗效。
Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.
作者信息
Kaatz G W, Seo S M, Aeschlimann J R, Houlihan H H, Mercier R C, Rybak M J
机构信息
Department of Internal Medicine, School of Medicine, Department of Veteran's Affairs Medical Center, Wayne State University, Detroit, Michigan 48201, USA.
出版信息
Antimicrob Agents Chemother. 1998 Apr;42(4):981-3. doi: 10.1128/AAC.42.4.981.
Abstract
The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was compared with that of vancomycin by using the rabbit model of left-sided methicillin-resistant Staphylococcus aureus endocarditis. Animals received LY333328 or vancomycin (25 mg/kg of body weight every 24 or 8 h, respectively) for 4 days. These drugs were equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and tissues. We conclude that in this model, LY333328 was microbiologically effective and may be a therapeutic alternative to vancomycin.
摘要
通过使用左侧耐甲氧西林金黄色葡萄球菌心内膜炎的兔模型，将新型糖肽类抗生素LY333328的体内疗效与万古霉素进行了比较。动物分别接受LY333328或万古霉素（分别每24小时或8小时25mg/kg体重），持续4天。这些药物在清除菌血症以及减少赘生物和组织中的细菌数量方面同样有效。我们得出结论，在该模型中，LY333328在微生物学上是有效的，可能是万古霉素的一种治疗替代药物。
相似文献
1
Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.LY333328治疗实验性耐甲氧西林金黄色葡萄球菌心内膜炎的疗效。
Antimicrob Agents Chemother. 1998 Apr;42(4):981-3. doi: 10.1128/AAC.42.4.981.
2
Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.万古霉素和新型半合成糖肽Ly333328对耐甲氧西林金黄色葡萄球菌的细胞内活性。
Infection. 1998 May-Jun;26(3):165-7. doi: 10.1007/BF02771843.
3
Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.ME1036对耐甲氧西林金黄色葡萄球菌实验性诱导的心内膜炎的治疗效果。
Antimicrob Agents Chemother. 2005 Aug;49(8):3526-8. doi: 10.1128/AAC.49.8.3526-3528.2005.
4
Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.利奈唑胺单独使用或与万古霉素联合使用治疗耐甲氧西林金黄色葡萄球菌所致实验性心内膜炎的疗效。
Antimicrob Agents Chemother. 2003 Sep;47(9):3002-4. doi: 10.1128/AAC.47.9.3002-3004.2003.
5
Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.达托霉素与替考拉宁和万古霉素治疗实验性金黄色葡萄球菌心内膜炎的比较。
Antimicrob Agents Chemother. 1990 Nov;34(11):2081-5. doi: 10.1128/AAC.34.11.2081.
6
Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.达托霉素对耐甲氧西林和糖肽类中介金黄色葡萄球菌引起的实验性心内膜炎治疗有效。
Antimicrob Agents Chemother. 2008 Jul;52(7):2538-43. doi: 10.1128/AAC.00510-07. Epub 2008 Apr 21.
7
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.在兔心内膜炎模型中，新型广谱头孢菌素头孢洛林（PPI-0903）与利奈唑胺和万古霉素相比，对耐甲氧西林和万古霉素中介金黄色葡萄球菌的体内疗效。
Antimicrob Agents Chemother. 2007 Sep;51(9):3397-400. doi: 10.1128/AAC.01242-06. Epub 2007 Jun 25.
8
Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.氟罗沙星在实验性耐甲氧西林金黄色葡萄球菌心内膜炎中的疗效。
Antimicrob Agents Chemother. 1989 Apr;33(4):519-21. doi: 10.1128/AAC.33.4.519.
9
Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.糖肽类药物在兔心内膜炎模型中对金黄色葡萄球菌感染的活性：最低抑菌浓度不能预测体内疗效。
Antimicrob Agents Chemother. 2005 Feb;49(2):857-9. doi: 10.1128/AAC.49.2.857-859.2005.
10
Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.LY333328在耐万古霉素粪肠球菌所致实验性心内膜炎中的活性与扩散
Antimicrob Agents Chemother. 1999 Jan;43(1):115-20. doi: 10.1128/AAC.43.1.115.
引用本文的文献
1
New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.感染性心内膜炎的新型抗菌药物及新治疗策略：需加以捍卫的武器
J Clin Med. 2023 Dec 14;12(24):7693. doi: 10.3390/jcm12247693.
2
Enhancing A82846B production by artificial attB-assisted overexpression of orf10-orf11 genes in Kibdelosporangium aridum SIPI-3927.通过人工attB辅助在干旱小孢囊菌SIPI-3927中过表达orf10-orf11基因来提高A82846B的产量。
AMB Express. 2020 Mar 16;10(1):52. doi: 10.1186/s13568-020-00992-x.
3
Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.耐甲氧西林金黄色葡萄球菌人工心脏瓣膜心内膜炎：病理生理学、流行病学、临床表现、诊断和治疗。
Clin Microbiol Rev. 2019 Feb 13;32(2). doi: 10.1128/CMR.00041-18. Print 2019 Mar 20.
4
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.奥利万星：一种新型糖肽类抗生素，用于治疗革兰氏阳性感染。
Infect Dis Ther. 2016 Mar;5(1):1-15. doi: 10.1007/s40121-016-0103-4. Epub 2016 Feb 1.
5
Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.糖肽类抗生素在革兰阳性感染中的应用：比较综述。
Drugs. 2015 Dec;75(18):2073-95. doi: 10.1007/s40265-015-0505-8.
6
Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.奥利万星在兔体内的药代动力学及骨渗透情况
Antimicrob Agents Chemother. 2015 Oct;59(10):6501-5. doi: 10.1128/AAC.00981-15. Epub 2015 Aug 3.
7
Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections.奥塔万星概述及其在治疗急性细菌性皮肤结构感染中的潜力。
Infect Drug Resist. 2015 Jul 6;8:189-97. doi: 10.2147/IDR.S69412. eCollection 2015.
8
Oritavancin for acute bacterial skin and skin structure infections.奥利万星用于治疗急性细菌性皮肤及皮肤结构感染。
Expert Opin Pharmacother. 2015 May;16(7):1091-8. doi: 10.1517/14656566.2015.1026256. Epub 2015 Mar 24.
9
Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.奥利万星治疗急性细菌性皮肤和皮肤结构感染：一项基于证据的综述
Core Evid. 2015 Feb 11;10:39-47. doi: 10.2147/CE.S51284. eCollection 2015.
10
New antimicrobial agents as therapy for resistant gram-positive cocci.新型抗菌药物用于耐药革兰氏阳性球菌的治疗
Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):3-15. doi: 10.1007/s10096-007-0389-y.
本文引用的文献
1
Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.对万古霉素敏感性降低的金黄色葡萄球菌——美国，1997年
MMWR Morb Mortal Wkly Rep. 1997 Aug 22;46(33):765-6.
2
Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996.1996年日本金黄色葡萄球菌对万古霉素的敏感性降低
MMWR Morb Mortal Wkly Rep. 1997 Jul 11;46(27):624-6.
3
Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.半合成糖肽类药物LY333328对万古霉素敏感和耐药的屎肠球菌菌株的时间杀菌曲线。
Antimicrob Agents Chemother. 1997 Jun;41(6):1407-8. doi: 10.1128/AAC.41.6.1407.
4
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.新型糖肽类药物LY333328的药效学评价及其对金黄色葡萄球菌和粪肠球菌的体外活性
Antimicrob Agents Chemother. 1997 Jun;41(6):1307-12. doi: 10.1128/AAC.41.6.1307.
5
In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.新型糖肽衍生物LY333328的体外活性及抗菌谱
Antimicrob Agents Chemother. 1997 Feb;41(2):488-93. doi: 10.1128/AAC.41.2.488.
6
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.研究性糖肽类抗生素LY333328对肠球菌和葡萄球菌的体外活性。
Antimicrob Agents Chemother. 1996 Oct;40(10):2416-9. doi: 10.1128/AAC.40.10.2416.
7
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.源自LY264826的半合成糖肽类抗生素，对耐万古霉素肠球菌具有活性。
Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9. doi: 10.1128/AAC.40.9.2194.
8
Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.由对万古霉素、青霉素和庆大霉素高度耐药的屎肠球菌引起的医院感染暴发。
Clin Infect Dis. 1993 Jun;16(6):750-5. doi: 10.1093/clind/16.6.750.
9
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.临床分离株中出现的多重耐药肠球菌。一、美国97个医学中心监测研究的患病率数据。肠球菌研究组。
Diagn Microbiol Infect Dis. 1995 Feb;21(2):85-93. doi: 10.1016/0732-8893(94)00147-o.
10
Automated fluorescence polarization immunoassay for monitoring vancomycin.用于监测万古霉素的自动化荧光偏振免疫测定法。
Ther Drug Monit. 1983;5(3):341-5. doi: 10.1097/00007691-198309000-00017.
Zotero 插件